Literature DB >> 7656957

Rat diaphragm contractility and histopathology are affected differently by low dose treatment with methylprednisolone and deflazacort.

P N Dekhuijzen1, G Gayan-Ramirez, A Bisschop, V de Bock, R Dom, R Bouillon, M Decramer.   

Abstract

The extent to which treatment with low doses of the nonfluorinated steroid methylprednisolone affects diaphragm contractility and morphology is unknown. In the present study, we compared the effects of equipotent doses of methylprednisolone and deflazacort, an oxazoline derivate of prednisolone with less systemic side-effects on bone structure and carbohydrate metabolism. Twenty six male adult rats were randomized to receive daily saline (control), methylprednisolone 0.4 mg.kg-1 or deflazacort 0.5 mg.kg-1 i.m. Contractile properties and histopathology were measured after a 6 week treatment period. During treatment, body weight increased in control and methylprednisolone-treated animals, but decreased by 4.2 +/- 1.1% (mean +/- SD) in the deflazacort group. Similarly, diaphragm mass in the deflazacort group was decreased compared to control and methylprednisolone groups. Twitch tension and twitch characteristics of isolated diaphragm bundles were similar in the three groups. Maximal tetanic tension was decreased in the deflazacort group. The force-frequency curve of the deflazacort bundles shifted downwards compared to control. Fatigue occurring during this protocol was greatest in the methylprednisolone- and deflazacort-treated animals. Microscopic examination revealed no gross abnormalities in the three groups. Histochemical analysis after staining for myosin adenosine triphosphatase (ATP-ase) showed that in the deflazacort group cross-sectional area of type I, IIa and IIb fibres were decreased. We conclude that low doses of methylprednisolone caused subtle and negligible changes in rat diaphragm contractile properties without affecting fibre dimensions, while deflazacort at an equipotent dose induced generalized fibre atrophy and changes in diaphragm contractility.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7656957

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  5 in total

Review 1.  Respiratory muscle injury in animal models and humans.

Authors:  W D Reid; N A MacGowan
Journal:  Mol Cell Biochem       Date:  1998-02       Impact factor: 3.396

2.  Myxomavirus Serp-1 Protein Ameliorates Inflammation in a Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Alexander B Andre; Liqiang Zhang; Jalen D Nix; Nora Elmadbouly; Alexandra R Lucas; Jeanne Wilson-Rawls; Alan Rawls
Journal:  Biomedicines       Date:  2022-05-17

3.  Corticosteroid effects on ventilator-induced diaphragm dysfunction in anesthetized rats depend on the dose administered.

Authors:  Karen Maes; Anouk Agten; Ashley Smuder; Scott K Powers; Marc Decramer; Ghislaine Gayan-Ramirez
Journal:  Respir Res       Date:  2010-12-14

Review 4.  Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?

Authors:  Stephanie Kourakis; Cara A Timpani; Dean G Campelj; Patricia Hafner; Nuri Gueven; Dirk Fischer; Emma Rybalka
Journal:  Orphanet J Rare Dis       Date:  2021-03-04       Impact factor: 4.123

5.  Skeletal Muscle Response to Deflazacort, Dexamethasone and Methylprednisolone.

Authors:  Alan Fappi; Juliana de Carvalho Neves; Leandro Nunes Sanches; Pedro Victor Massaroto E Silva; Guilherme Yuiti Sikusawa; Thayane Pereira Correa Brandão; Gerson Chadi; Edmar Zanoteli
Journal:  Cells       Date:  2019-05-01       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.